A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial

CONCLUSIONS: Our findings support the use of DAT in the majority of patients. A small subgroup of patients might benefit from TAT and we propose a novel clinical risk score to select these patients.PMID:35105533 | DOI:10.4244/EIJ-D-21-00165

Source: EuroIntervention - February 2, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Bastiaan Zwart Willem Lambertus Bor Anne Johanna Wilhelmina Maria de Veer Bakhtawar Khan Mahmoodi Johannes Christiaan Kelder Gregory Y H Lip Deepak L Bhatt Christopher P Cannon Jurri ën Maria Ten Berg Source Type: research